AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02011750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either the experimental Sodium Valproate (Depakote, or DEP) or placebo (PLA) group in a 1:1 proportion. For the PLA group, this will be followed by a two week period of placebo during which members of the experimental Sodium Valproate (Depakote/DEP) will have DEP dose adjusted to attain therapeutic levels (50-100 µg/mL). Then PLA treatment will continue for 16 more weeks. Subjects will be followed up for four weeks post PLA-discontinuation to monitor for delayed adverse side effects.
Study NCT02011750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either the experimental Sodium Valproate (Depakote, or DEP) or placebo (PLA) group in a 1:1 proportion. For the PLA group, this will be followed by a two week period of placebo during which members of the experimental Sodium Valproate (Depakote/DEP) will have DEP dose adjusted to attain therapeutic levels (50-100 µg/mL). Then PLA treatment will continue for 16 more weeks. Subjects will be followed up for four weeks post PLA-discontinuation to monitor for delayed adverse side effects.
Study NCT03642522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation
Description: rTMS is a Health-Canada- and FDA-approved treatment for treatment-resistant depression (TRD), using focused magnetic field pulses to stimulate brain regions involved in emotion regulation, safely and non-invasively. rTMS can be applied at varying discharge frequencies which have differential effects on cortical excitability. At a low frequency (≤ 1Hz), rTMS reduces cortical excitability, while at frequencies greater than 1 Hz, rTMS facilitates cortical excitability3. In MDD, either high- frequency rTMS (HF-rTMS) applied over the left dorsolateral prefrontal cortex (DLPFC) or low- frequency rTMS (LF-rTMS) applied over the right DLPFC have similar efficacy. This study utilizes low frequency rTMS to the right DLPFC.
Study NCT00003621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Study NCT00003621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00003621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00003621 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01782482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lens with color
Description: Silicone hydrogel contact lens with color
Study NCT01782482 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phemfilcon A contact lens with color
Description: Hydrogel contact lens with color
Study NCT03867955 — intervention group
Intervention type: OTHER
Intervention: Collection of datas
Description: Collection of datas by videopupillometer results: pupil diameter and variation of the pupillary diameter.
Study NCT04107155 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Weight Management Formulation
Description: Saffron extract and Gynostemma extract with hesperidin
Study NCT04107155 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03547583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo and sham up-titration at weeks 2, 4, and 6
Study NCT03501290 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fortimel® Protein supplementation
Description: Patients are supposed to take Fortimel® Protein once daily during the study period. The prescription is one unit a day.~First prescription of the study product will be done for one month. Prescription will be repeated for 2 additional months only after the patient's nutritional status and its global health status, as well as tolerability and compliance to the ONS, were re-assessed during the first follow-up visit at one month.
Study NCT02998567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: In arm 1 (escalation) and 2 (expansion).
Study NCT02998567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: In arm 1 (escalation) and 2 (expansion).
Study NCT03791905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET
Description: Using PET to evaluate response to induction chemotherapy
Study NCT04107155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handout with Suggestions for Healthy Eating and Overall Health
Description: Suggestions for Healthy Eating and Overall Health
Study NCT04107155 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Handout with Suggestions for Healthy Eating and Overall Health
Description: Suggestions for Healthy Eating and Overall Health
Study NCT01478737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal dexamethasone implant
Description: Intravitreal Ozurdex after vitrectomy
Study NCT01444105 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iStent
Description: Implantation of two iStent devices
Study NCT01444105 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SLT
Description: Laser treatment
Study NCT03728933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine 1 milligram/24 hours
Description: Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 1 milligram (mg)/24 hours (h) (5 square centimeter (cm\^2) patch size).
Study NCT03728933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine 2 milligram/24 hours
Description: Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 2 milligram (mg)/24 hours (h) (10 square centimeter (cm\^2) patch size).
Study NCT03728933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: not applicable
Study NCT00582907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilonacept
Description: 2.2 mg/kg/wk by subcutaneous injection, for 3 months
Study NCT00582907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo by subcutaneous injection weekly for 3 months
Study NCT01204788 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic White Cell Transfusion
Description: Radiated white blood cell transfusions 2-3 times each week, or daily if infection develops
Study NCT01204788 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic White Cell Transfusion
Description: Radiated white blood cell transfusions daily only with infection (or persistent fever)
Study NCT00639457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Oral 30mg/day for 16 weeks
Study NCT00639457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Oral 30mg/day for 16 weeks
Study NCT00639457 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Supervised aerobic and resistance exercise training (1.5hrs/day x 3 days/wk) for 16 weeks
Study NCT02998567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: In arm B2 (lung expansion) replacing guadecitabine
Study NCT01785069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatomically shaped, silicone-filled breast implants with low projection or extra-full projection
Description: Surgical implant
Study NCT03144960 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mechanical Thrombectomy
Description: mechanical thrombectomy with retrievable stents, thrombus aspiration, retraction, wire disruption
Study NCT01364233 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MotifMESH
Description: Polytetrafluoroethylene (cPTFE) macroporous mesh
Study NCT02658994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thinking Healthy Program Peer Delivered Plus
Study NCT02658994 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Study NCT04103398 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TACE+sorafenib
Description: The initial dose of sorafenib is 400mg BID and the drug therapy will last till outcome events happen or the trial ends. TACE will start one day following oral sorafenib. Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (doxorubicin 50mg for cTACE or 75mg for dTACE) and embolizing agents (gelatin sponge for cTACE or microsphere for dTACE) into blood vessels that help tumor grow.
Study NCT04103398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (doxorubicin 50mg for cTACE or 75mg for dTACE) and embolizing agents (gelatin sponge for cTACE or microsphere for dTACE) into blood vessels that help tumor grow.
Study NCT05084794 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal fixation
Description: Fixation of posterior malleolus with either plate or screws.
Study NCT01573507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sodium lactate infusion
Description: 3-6 hours continuous infusion of sodium lactate (20-40 mcg/kg/min)
Study NCT01380444 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gamma3 Intramedullary Nails (Stryker)
Description: The Gamma3 nail is cannulated for Guide-Wire-controlled insertion, and features a conical tip for optimal alignment with the inner part of the cortical bone. A single distal Locking Screw is provided to stabilize the nail in the medullary canal and to help to prevent rotation in complex fractures.
Study NCT01380444 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sliding Hip Screws
Description: The sliding hip screw is a single larger diameter partially threaded screw, which is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixation.
Study NCT01689844 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DASH Plus
Description: DASH diet advice and guided shopping for high postassium foods at a local supermarket
Study NCT01689844 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DASH - C
Description: Brief DASH dietary advice, No shopping guidance at the local supermarket.
Study NCT02579239 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATYR1940
Description: Concentrate for solution for infusion
Study NCT01709136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Single dose SRL pharmacokinetics and TAC steady state pharmacokinetics: This phase is applicable to both sets of patients: those with nephrotoxicity and those with hypertension. Patients will receive a single dose of SRL of 2 mg/m2. Blood sampling will be performed over a 24 hour stay in the Children's Hospital of Pittsburgh's Pediatric Clinical and Translational Research Center (PCTRC) - See more at: http://www.chp.edu/research/our-facilities/pctrc, and the sampling for 48 hour and 72 hour PK studies can be done at the outpatient lab. This phase can either be performed immediately after the 12-hour iothalamate GFR evaluation, or a few days later at the convenience of the subject.
Study NCT00212303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training for 6 months
Description: Exercise 3 times/week for 6 months. Exercise consists of aerobic and resistance exercise
Study NCT04363437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: People in the colchine group will be given a starting dose of 1.2 mg followed, by 0.6mg after 2 hours if they do not have significant gastrointestinal symptoms, on day 1. After that, they will take colchicine 0.6mg twice a day for 14 days or until discharged or release from the hospital.
Study NCT04363437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: COVID Patients in this arm will receive usual care COVID19 treatment and will not receive colchine.
Study NCT01527227 — intervention group
Intervention type: OTHER
Intervention: questionnaires
Description: The research will examine effects of personal, familial, societal and intergenerational characteristics on parentification, the effects of parentification on the quality of life of the child and what encourages a better quality of life.
Study NCT00286130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan
Study NCT00286130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX 6
Description: FOLFOX 6:~* Oxaliplatin 100 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks:
Study NCT00286130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: FOLFIRI:~* Irinotecan 180 mg/m² day 1 concurrent with~* Leucovorin 400 mg/m² followed by~* Bolus 5FU 400 mg/m², followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks
Study NCT01079533 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped CRCS Interventions
Description: In Step 1, we will evaluate a theory-based minimal cue delivered by a letter, telephone call, or automated telephone call. Persons who do not complete CRCS in Step 1 will be randomized to Step 2 using principles of Motivation Interviewing. Step 2 also will determine whether an automated approach, telephone-linked communication (TLC), is as effective as a telephone counselor in promoting initiation of CRCS. Steps 1 and 2 together will address the important issue of the dose needed to encourage completion of CRCS.
Study NCT01079533 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: A survey-only control arm will be compared to the experimental arm to determine whether the 3 different delivery channels are equally efficacious and cost-effective.
Study NCT01605344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI.
Description: All patients will receive FOLFIRI infusion on day 1 and day 15.
Study NCT01605344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: A subjects will receive atorvastatin 20 mg orally once daily given for two weeks starting on Day -14 during PERIOD ONE. ARM A will then receive no statin during PERIOD TWO. ARM B subjects will receive no atorvastatin during PERIOD ONE. ARM B subjects will receive atorvastatin 20 mg orally once daily for two weeks during PERIOD TWO (starting on Day 2). One cycle = 28 days.
Study NCT02681055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-001
Description: MN-001 is a novel, orally bioavailable small molecule compound which demonstrates anti-inflammatory activity
Study NCT03270553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plazomicin
Description: single intravenous dose
Study NCT03270553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: single oral dose
Study NCT02326467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: Bi-weekly chlorhexidine baths
Study NCT00434512 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV vaccine 732461
Study NCT02494388 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic ultrasound guided needle based confocal endomicroscopy
Description: Needle based confocal laser endomicroscopy is a technique that enables in vivo microscopic analysis during ongoing endoscopy. It has good accuracy for predicting the final histopathological diagnosis based on immediate evaluation of tissue and vascular patterns. nCLE microprobe is a flexible probe thin enough that it can be passed through a 19-gauge needle. Thus under EUS guidance solid organs (i.e. the pancreas) can be accessed for real-time microscopic information.
Study NCT04061252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4827
Description: brodalumab 210mg Q2W, SC
Study NCT04061252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Q2W, SC
Study NCT01974726 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ET Stress test
Description: Performed in pressure chamber. For subjects with intact tympanic membranes, chamber pressure increased from ambient to +2500 daPa (+2000 daPa for children). At that pressure and then at down-stepped pressures of 250 daPa/steps to a chamber pressure of -1500 daPa (or a passive ET opening), the subject will swallow to attempt to open the ET as detected by sonotubometry and/or a change in ear canal pressure. ET passive opening and closing pressures will then be determined. In ears with a non-intact tympanic membrane, a small volume probe connected to a pressure transducer will be placed in the ear canals and the procedure repeated with continuous recording of ME pressure. ET opening is recorded as a change in ME pressure toward local ambient.
Study NCT01974726 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sonotubometry
Description: Microphones are placed in the ear canals and covered with ear protectors. A nasal probe placed in one nostril introduces a white noise to the nasopharynx and the subject is asked to swallow. The test system identifies the sound frequency best transmitted through an open ET (if the test is positive, i.e. ET opens) and the procedure is repeated with the nasal sound pressure delivered at that frequency. The probe is then placed in the contralateral nostril and the procedure repeated. The microphone signals from both ear canals are continuously outputted and recorded. A positive ET opening is defined as a 5 dB increase above baseline during any of the 4 swallows and can be semi-quantified as the area under the baseline-adjusted ear canal sound pressure-time curve. The test is designed to measure the presence or absence of muscle-assisted ET openings during swallowing at local ambient pressure.
Study NCT01974726 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Forced Response Test (FRT)
Description: The FRT requires a non-intact tympanic membrane and uses an instrument consisting of an ear canal probe coupled serially to a differential pressure transducer, via a valve to a flow sensor and via a second valve to a variable-speed constant-flow pump. The probe is sealed in the ear canal and both valves are opened. The pump is set to deliver a constant flow of 11 ml/min which increases ME pressure to passively open the ET. This is followed by a decrease in ME pressure to steady state pressure and flow conditions. The subject is asked to swallow which either transiently increases (further ET dilation) or decreases (ET constriction) the transET flow. The pump is turned off causing the ET to close at a residual ME pressure. This procedure is repeated at flow rates of 23 and then 46 ml/min.
Study NCT01974726 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Inflation Deflation Test (IDT)
Description: The IDT requires a non-intact tympanic membrane and uses the FRT instrument. ME pressure is increased to 250 daPa (ref ambient), the valves to the flow sensor and pump closed and the subject is asked to swallow repeatedly at a natural interval while monitoring ME pressure until further swallowing fails to change ME pressure. The procedure is repeated with an applied under-pressure of -250 daPa. The outcome variable is the percent pressure change (%reduction) at test end. The test measures the muscle-assisted tubal openings under minor stress (ME under-pressure) and facilitative (ME over-pressure) conditions, and can detect a patulous/semi-patulous ET by an inability to maintain applied ME over and/or under-pressures between swallows.
Study NCT01974726 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Maneuver Sequence
Description: The sequence consists of the Toynbee, Valsalva, Sniffing and Continuous Pressure Test (CPT). The test system consists of ear canal and nasal pressure probes. For the Toynbee test the subject pinches both nostrils (without constricting the nasal probe) and swallows; for the Sniffing test, the subject performs a series of forcible sniffs that must achieve a nasopharyngeal pressure of at least -400 daPa; for the Valsalva test the subject pinches both nostrils and forcibly blows against the closed nose to achieve a nasopharyngeal pressure of at least 400 daPa, and for the CPT the subject breathes through his/her mouth in a relaxed manner for 2 minutes.
Study NCT01974726 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 9-Step Test
Description: This test requires an intact tympanic membrane. Middle ear (ME) pressure is recorded by tympanometry before and after application of a 300 daPa over-pressure to the ear canal and then before and after application of a 300 daPa under-pressure to the ear canal. Between steps, the subject is asked to swallow in an attempt to open the ET and change ME pressure. A positive test is indicated by a minimum 10 daPa change in ME pressure after a given swallow and excellent muscle-assisted ET opening is indicated by an initial change to a more negative ME pressure after a swallow, followed by a return to 0 daPa, a positive ME pressure and a return to 0 daPa for sequential swallows. The test is designed to measure the presence/absence of active ET openings during swallowing at ambient pressures.